Cyclacel
Research & Development

Clinical Trials

Cyclacel Pharmaceuticals is currently evaluating the following oncology drug candidates in clinical trials:

  • CYC065: CYC065 is a highly-selective, second generation inhibitor of CDK2 and CDK9 that causes apoptotic death of cancer cells at sub-micromolar concentrations and is bioavailable via oral and intravenous routes.

    Learn more about CYC065 trial(s) on ClinicalTrials.gov

  • Seliciclib (CYC202): seliciclib is an orally-available cyclin-dependent kinases (CDKs) inhibitor. The compound selectively inhibits enzyme targets CDK2, CDK7 and CDK9 that are central to the process of cell division and cell cycle control.

    Learn more about seliciclib trial(s) on ClinicalTrials.gov

  • Sapacitabine (CYC682): sapacitabine is an orally-available nucleoside analogueue with a novel mechanism; interfering with DNA synthesis by introducing single-strand DNA breaks leading to arrest of cell cycle progression in G2-Phase and development of double-strand DNA breaks.

    Learn more about sapacitabine trial(s) on ClinicalTrials.gov

These candidates are experimental drugs under clinical investigation. They are not approved for human use.






 

Research & Development